Premier Alternatives

Crossbow Therapeutics

Cambridge, MA · Founded 2021 · Privately Held (backing)

Developer of a biotechnology company intended to enhance the quality of life for individuals suffering from cancer. Crossbow Therapeutics is based in Cambridge, MA and was founded in 2021. Its last reported valuation was $125 million in Jul 2023. It has raised $198 million across 2 recorded rounds; the latest was a $30.3 million early-stage round in Sep 2025.

Last reported valuation
$125.0M
Oct 2026
Priced at
—
Total raised
$198.3M
Last round
Early Stage VC
Sep 2025

Crossbow Therapeutics key facts

as of Oct 2026
  • Developer of a biotechnology company intended to enhance the quality of life for individuals suffering from cancer.
  • Crossbow Therapeutics is valued at approximately $125.0M as of Oct 2026 (last reported valuation).
  • It has raised $198.3M across 2 recorded rounds; the latest was Early Stage VC ($30.3M) in Sep 2025.
  • Notable investors include Mirae Asset Capital, Arkin Capital, Pfizer Ventures, Eli Lilly and Company Foundation, MPM BioImpact — 13 tracked in total.
  • Crossbow Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Sep 2025 ($30.3M sold to 17 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$125.0M

Crossbow Therapeutics's last reported valuation, Jul 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Crossbow Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Crossbow Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Crossbow Therapeutics funding rounds

2 rounds
Sep 2025Early Stage VC$30.3MSEC filing▮
Mar 2023Early Stage VC$37.6MSEC filing▮
Full funding history →

Crossbow Therapeutics valuation

Crossbow Therapeutics's last reported valuation was $125 million in Jul 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Crossbow Therapeutics raised?

Crossbow Therapeutics has raised $198 million in total; 2 of its rounds are on record. The largest on record was a $37.6 million early-stage round in Mar 2023; the most recent was a $30.3 million early-stage round in Sep 2025.

Crossbow Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently in Sep 2025 ($30.3 million sold to 17 investors).

Crossbow Therapeutics investors

13 investors are on record for Crossbow Therapeutics, including Mirae Asset Capital, Arkin Capital, Pfizer Ventures and Eli Lilly and Company Foundation. The early-stage round in Sep 2025 drew 17 investors.

About Crossbow Therapeutics

Developer of a biotechnology company intended to enhance the quality of life for individuals suffering from cancer. The company's therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets, an efficient and selective approach to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer, enabling patients to improve their lives by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2021
Employees
41
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.